BlackRock’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $224M | Buy |
6,880,290
+268,416
| +4% | +$8.63M | ﹤0.01% | 1597 |
|
|
2025
Q4 | $233M | Buy |
6,611,874
+1,015,708
| +18% | +$36M | ﹤0.01% | 1581 |
|
|
2025
Q3 | $147M | Buy |
5,596,166
+158,658
| +3% | +$4.73M | ﹤0.01% | 1848 |
|
|
2025
Q2 | $144M | Sell |
5,437,508
-538,960
| -9% | -$14.2M | ﹤0.01% | 1814 |
|
|
2025
Q1 | $144M | Buy |
5,976,468
+103,490
| +2% | +$3.27M | ﹤0.01% | 1778 |
|
|
2024
Q4 | $236M | Buy |
5,872,978
+492,655
| +9% | +$28.1M | ﹤0.01% | 1581 |
|
|
2024
Q3 | $341M | Sell |
5,380,323
-645,808
| -11% | -$37.9M | 0.01% | 1344 |
|
|
2024
Q2 | $319M | Sell |
6,026,131
-2,248,043
| -27% | -$147M | 0.01% | 1303 |
|
|
2024
Q1 | $678M | Buy |
8,274,174
+668,307
| +9% | +$29.7M | 0.02% | 823 |
|
|
2023
Q4 | $142M | Buy |
7,605,867
+474,950
| +7% | +$6.21M | ﹤0.01% | 1875 |
|
|
2023
Q3 | $78.9M | Buy |
7,130,917
+235,994
| +3% | +$3.38M | ﹤0.01% | 2125 |
|
|
2023
Q2 | $112M | Buy |
6,894,923
+4,854,645
| +238% | +$102M | ﹤0.01% | 1971 |
|
|
2023
Q1 | $34M | Buy |
2,040,278
+694,265
| +52% | +$7.17M | ﹤0.01% | 2690 |
|
|
2022
Q4 | $12.7M | Sell |
1,346,013
-120,243
| -8% | -$537K | ﹤0.01% | 3278 |
|
|
2022
Q3 | $3.99M | Buy |
1,466,256
+39,035
| +3% | +$128K | ﹤0.01% | 3853 |
|
|
2022
Q2 | $4.12M | Sell |
1,427,221
-3,720,240
| -72% | -$9.21M | ﹤0.01% | 3908 |
|
|
2022
Q1 | $15.4M | Buy |
5,147,461
+27,971
| +0.5% | +$100K | ﹤0.01% | 3332 |
|
|
2021
Q4 | $23.5M | Sell |
5,119,490
-1,643
| -0% | -$9.21K | ﹤0.01% | 3178 |
|
|
2021
Q3 | $32.2M | Sell |
5,121,133
-118,917
| -2% | -$735K | ﹤0.01% | 2960 |
|
|
2021
Q2 | $31.4M | Sell |
5,240,050
-87,060
| -2% | -$517K | ﹤0.01% | 3024 |
|
|
2021
Q1 | $33.7M | Buy |
5,327,110
+10,773
| +0.2% | +$75.8K | ﹤0.01% | 2877 |
|
|
2020
Q4 | $29.9M | Buy |
5,316,337
+605,585
| +13% | +$3.67M | ﹤0.01% | 2794 |
|
|
2020
Q3 | $27.4M | Sell |
4,710,752
-76,993
| -2% | -$530K | ﹤0.01% | 2684 |
|
|
2020
Q2 | $34.5M | Buy |
4,787,745
+40,052
| +0.8% | +$266K | ﹤0.01% | 2467 |
|
|
2020
Q1 | $22.2M | Buy |
4,747,693
+40,432
| +0.9% | +$249K | ﹤0.01% | 2554 |
|
|
2019
Q4 | $37.8M | Buy |
4,707,261
+211,544
| +5% | +$1.54M | ﹤0.01% | 2531 |
|
|
2019
Q3 | $30.9M | Buy |
4,495,717
+100,332
| +2% | +$745K | ﹤0.01% | 2568 |
|
|
2019
Q2 | $36.5M | Buy |
4,395,385
+280,919
| +7% | +$2.4M | ﹤0.01% | 2512 |
|
|
2019
Q1 | $40.9M | Buy |
4,114,466
+15,060
| +0.4% | +$126K | ﹤0.01% | 2386 |
|
|
2018
Q4 | $31.4M | Buy |
4,099,406
+749,505
| +22% | +$8.96M | ﹤0.01% | 2488 |
|
|
2018
Q3 | $58.4M | Buy |
3,349,901
+411,256
| +14% | +$4.89M | ﹤0.01% | 2292 |
|
|
2018
Q2 | $27.9M | Buy |
2,938,645
+2,562,356
| +681% | +$17M | ﹤0.01% | 2675 |
|
|
2018
Q1 | $1.65M | Buy |
376,289
+375,586
| +53,426% | +$2.08M | ﹤0.01% | 3729 |
|
|
2017
Q4 | $3K | Hold |
703
| – | – | ﹤0.01% | 4774 |
|
|
2017
Q3 | $1K | Hold |
703
| – | – | ﹤0.01% | 4925 |
|
|
2017
Q2 | $1K | Hold |
703
| – | – | ﹤0.01% | 4980 |
|
|
2017
Q1 | $1K | Buy |
+703
| New | +$983 | ﹤0.01% | 4965 |
|
Other funds holding VKTX
VCM
VPM
BlackRock's VKTX Position: Q1 2026 in Review
BlackRock increased its Viking Therapeutics (VKTX) stake by 4.1% in Q1 2026, buying an estimated $8.63M and bringing the position to 6,880,290 shares worth $224M. The position accounts for ﹤0.01% of the portfolio, ranked #1597.
BlackRock first reported a position in VKTX in Q1 2017 and has held it in 37 quarters since. The position peaked at $678M in Q1 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- BlackRock held 6,880,290 shares of Viking Therapeutics worth $224M as of Q1 2026.
- BlackRock bought 268,416 Viking Therapeutics shares in Q1 2026, an estimated $8.63M.
- Viking Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #1597 holding.
- BlackRock first reported a position in Viking Therapeutics in Q1 2017 and has held it in 37 quarters since.
- BlackRock's Viking Therapeutics position peaked at $678M in Q1 2024.
- 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.